Osmotic system with laminated wall comprising structurally different semipermeable lamina

ABSTRACT

An osmotic system for delivering a beneficial agent to an environment of use is disclosed. The system comprises a laminate surrounding a compartment and has a passageway through the laminate for releasing agent from the compartment. The laminate comprises at least two laminae; one consisting of a semipermeable, polymeric material that is permeable to the passage of an external fluid and maintains its physical and chemical integrity in the environment of use, and one consisting of a semipermeable polymeric material that is permeable to the passage of fluid, substantially impermeable to the passage of agent and maintains its physical and chemical integrity in the presence of agent. The compartment comprises an active agent that is either soluble in the external fluid and exhibits an osmotic pressure gradient across the laminate against the fluid, or the agent has limited solubility in the fluid and it is mixed with an osmotically effective compound that is soluble in the fluid and exhibits an osmotic pressure gradient across the laminate against the fluid. In operation, agent is released from the system by fluid being imbibed through the laminate into the compartment at a rate controlled by the permeability of the laminate and the osmotic pressure gradient across the laminate producing a solution containing agent, or a solution of compound containing agent which solution in either operation is released through the passageway at a controlled and continuous rate over a prolonged period of time.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. Pat. App. Ser. No. 654,194,filed on Feb. 2, 1976 and now matured into U.S. Pat. No. 4,014,334. Thisapplication and Ser. No. 654,194 are assigned to the ALZA Corporation ofPalo Alto, Calif., and benefit of the filing date of Ser. No. 654,194 isclaimed herein.

FIELD OF THE INVENTION

This invention pertains to an osmotic system. More particularly, theinvention relates to an osmotic system in the form of an osmotic devicecomprising a semipermeable laminate formed of at least two, non-erodibleand inert polymeric semipermeable laminae for delivering an active agentat a controlled and continuous rate over a prolonged period of time toan environment of use.

BACKGROUND OF THE INVENTION

Osmotic systems manufactured in the form of osmotic devices fordelivering a beneficial agent to an environment of use are known to theart in U.S. Pat. Nos. 3,845,770 and 3,916,899. The systems in thesepatents are made with a semipermeable wall that surrounds a compartmentcontaining an agent. The wall is permeable to an external fluid,substantially impermeable to agent, and there is a passageway throughthe wall for dispensing agent from the system. These systems areextraordinarly effective for delivering an agent that is soluble in thefluid and exhibits an osmotic pressure gradient across the wall againstthe fluid, and also for delivering an agent that has limited solubilityin the fluid and is admixed with an osmotically effective compound thatis soluble in the fluid and exhibits an osmotic pressure gradient acrossthe wall against the fluid. These systems release agent by fluid beingcontinuously imbibed through the wall into the compartment at a ratedetermined by the permeability of the wall and the osmotic pressuregradient across the wall to produce a solution of soluble agent, or asolution of soluble compound containing agent which solution in eitheroperation is dispensed from the system. While the above systems areoutstanding and represent a pioneer advancement in the delivery art, andwhile they are useful for dispensing numerous beneficial agents to anenvironment of use, there is a rare instance where the environment orthe agent may have an unwanted effect on the system that can lead tounwanted results. For example, when the system is placed in anenvironment that can harm the wall, or the system contains an agent thatcan harm the wall, in either instance by slowly dissolving orhydrolyzing the wall over a prolonged period of time, these actions canchange the system's rate of imbibition that can concomitantly lead to anuncontrolled rate of agent release over a correspondingly prolongedperiod of time.

OBJECTS OF THE INVENTION

Accordingly, it is an immediate object of this invention to provide animproved osmotic system for the controlled and continuous dispensing ofan active agent over a prolonged period of time which system overcomesthe problems known to the prior art.

Another object of the invention is to provide an osmotic system thatmaintains its physical and chemical integrity in both the environment ofuse and in the presence of agent during the controlled and continuousdispensing of agent over a prolonged period of time.

Yet another object of the invention is to provide an osmotic systemdesigned with a minimum number of parts and having at least one wallformed as a laminate that is substantially non-erodible and inerttowards the environment, agents and solutions thereof.

Another object of the invention is to provide an osmotic therapeuticsystem for dispensing drugs that because of their intrinsic properties,are difficult to dispense, and which drugs can be dispensed with thesystems of this invention at a controlled and continuous rate to performtheir intended therapeutic effects.

Still a further object of the invention is to provide an osmotictherapeutic system that can administer a complete pharmaceutical regimento a human for a particular time period, the use of which requiresintervention only for initiation and possibly termination of theregimen.

Still a further object of the invention is to provide osmotic systemshaving a wide spectrum of semipermeable laminates in which propertiessuch as fluid flow-through rate and resistance to chemical andbiological attack may be regulated and varied by controlling the laminaeforming the laminates.

Yet still another object of the invention is to provide an osmoticsystem having a laminate that has a high flux rate to fluids, a highdegree of exclusion towards agents and improved resistance to hydrolysisand erosion in the enviroment of use and in the presence of agents overa wide pH range.

Yet still another object of the invention is to provide an osmoticsystem that can deliver all kinds of drugs and has an economic advantagefor the user by keeping to a minimum the number of doses to beadministered and reduces missed doses because of forgetfulness.

Other objects, features and advantages of the invention will be moreapparent to those skilled in the art from the following detailedspecification, taken in conjunction with the drawings and theaccompanying claims.

SUMMARY OF THE INVENTION

This invention concerns an osmotic system for dispensing an active agentto an environment of use. The system is comprised of a laminatesurrounding a compartment and has a passageway through the laminatecommunicating with the compartment and the exterior of the system. Thecompartment contains either an agent that is soluble in an externalfluid and exhibits an osmotic pressure gradient across the laminateagainst the fluid, or it contains a mixture of an agent having limitedsolubility in the fluid and an osmotically effective compound soluble inthe fluid that exhibits an osmotic pressure gradient across the laminateagainst the fluid. The laminate is comprised of at least twosemipermeable laminae, each consisting of a different semipermeable,polymeric lamina forming material, with the laminate permeable to fluid,substantially impermeable to agent and compounds, and inert towardsagent and the environment of use. Agent is released from the system byfluid being imbibed through the semipermeable laminate into thecompartment at a rate controlled by the permeability of the laminate andthe osmotic pressure gradient across the laminate producing a solutioncontaining agent that is released through the passageway at a controlledand continuous rate over a prolonged period of time.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, which are not drawn to scale, but are set forth toillustrate various embodiments of the invention, the figures are asfollows:

FIG. 1A is a view of an osmotic therapeutic system designed for orallydelivering a beneficial agent;

FIG. 1B is a view of the osmotic therapeutic system of FIG. 1A in openedsection illustrating the laminate and the compartment of the system;

FIG. 1C is a perpsective view of a portion of the laminate of FIG. 1Bwith one end peeled open showing the laminae that form the laminate;

FIG. 2 is a view of an osmotic therapeutic system manufactured fortopically administering a drug;

FIG. 3 shows an osmotic therapeutic system designed for releasing drugin the vaginal cavity;

FIG. 4 is a front view of the human eye illustrating an osmotictherapeutic system in operative position in an environment of use;

FIG. 5 is a graph comparing a lamina that is inert with a lamina thatslowly loses its integrity in the presence of agent;

FIG. 6 is a graph comparing the permeability of a laminate thatmaintains its integrity in the presence of fluid with a laminate thatslowly loses its integrity in the presence of fluid; and

FIG. 7 is a graph illustrating the inertness of a laminated wall towardsdrug and the environment of use.

In the drawings and specification, like parts in related figures areidentified by like numbers. The terms appearing earlier in thespecification and in the description of the drawings, as well asembodiments thereof, are further detailed elsewhere in the disclosure.

DETAILED DESCRIPTION OF THE DRAWINGS

Turning now to the drawings in detail, which are examples of variousosmotic delivery systems of the invention, and which examples are not tobe considered as limiting, one example of an osmotic delivery system inthe form of an osmotic device is indicated in FIGS. 1A, 1B and 1Cconsidered together by the numeral 10. The phrases "osmotic deliverysystem" and "osmotic delivery system in the form of an osmotic device"as used for the purpose of the invention are considered as functionalequivalents and they also embrace the expressions "osmotic therapeuticsystem", "osmotic device" and "system".

In FIGS. 1A, 1B and 1C, system 10 is comprised of a body 11 having alaminate 12 that surrounds a compartment 13, seen in FIG. 1B in openedsection with a portion of laminate 12 removed at 14, and a passageway 15in laminate 12 that communicates with compartment 13 and the exterior ofsystem 10. Compartment 13, as seen in FIG. 1B, in one embodiment is ameans for containing an agent 16 that is soluble in an external fluidand exhibits an osmotic pressure gradient across laminate 12 against anexternal fluid, or compartment 13 can contain a mixture of agents 16with at least one agent exhibiting an osmotic pressure gradient. Inanother embodiment, compartment 13 contains an agent that has limitedsolubility or is substantially insoluble in the external fluid is mixedwith an osmotically effective compound 17 that is soluble in theexternal fluid and exhibits an osmotic pressure gradient across laminate12 against the fluid. Compartment 13 also can contain other compoundssuch as a surfactant for wetting the agent and a non-toxic dye foreither identifying agent 16 or for making release of agent 16 visible tothe unaided eye.

Laminate 12, as seen in FIG. 1C, is a section removed from system 10 ofFIG. 1B and it is peeled open at 18 for illustrating the structure oflaminate 12. Laminate 12 comprises a pair of laminae consisting of anexterior lamina 19 and an inner lamina 20 that are suitably joined inlaminar relationship to provide an operative laminate 12 for system 10.Lamina 19 is formed of a unit, semipermeable polymeric lamina formingmaterial that in one embodiment is, (a) permeable to the passage of anexternal fluid, (b) maintains its physical and chemical integrity in theenvironment of use, (c) is inert in the environment of use, and (d)provides mechanical support for other laminae forming laminate 12.Lamina 19 is another embodiment is formed of a unit semipermeablepolymeric lamina forming material that is, (e) permeable to passage ofexternal fluid, (f) substantially impermeable to compounds present inthe environment of use, and has the properties described above in (b),(c) and (d). The phrase "maintains its physical and chemical integrity"as used herein means laminate 12 and laminae 19 and 20 keep theirconstitution and general preselected shape and design in the environmentof use, and in the presence of agent during the active period of agentrelease even though the system may be flexible and resilient. The terms"inert", "non-erodible" and "resist erosion" mean laminate 12 andlaminae 19 and 20 are substantially resistant to physical, chemical,enzymatic and biological attack and reactions in the particularenvironment of use and in the presence of agent in the compartment. Theterm "laminate" means the semipermeable laminate surrounding thecompartment, and is the functional equivalent of laminated wall andshaped laminated wall.

Lamina 20 is formed of a unit, semipermeable lamina forming materialthat in one embodiment is, (g) permeable to the passage of an externalfluid, (h) substantially impermeable to agent, (i) maintains itsphysical and chemical integrity in the presence of agent, (j) is inertin the presence of agent, and (k) provides mechanical support for otherlaminae forming laminate 12. Lamina 20 in another embodiment has theproperties described in (g) through (k) and also is, (l) substantiallyimpermeable to compounds present in the environment of use. Also,according to the mode and manner of this invention, laminae 19 and 20are each formed of a unit or sole semipermeable polymeric lamina formingmaterial that is physically and chemically different with lamina 20 in apresently preferred embodiment more hydrophobic than lamina 19, moreinert, having a higher degree of agent and compound rejection, andhaving a decrease permeability to the passage of an external fluid.While laminae 19 and 20 in a presently preferred embodiment weredescribed with lamina 19 positioned distant from compartment 13 withlamina 20 facing compartment 13, it is understood for other embodiments,lamina 20 can be distant from compartment 13 and lamina 19 can facecompartment 13. A detailed description of lamina forming materials,agents and other compounds appears later in the specification.

In operation in the environment of use, system 10 in one embodimentreleases agent 16 housed in compartment 13 and soluble in the externalfluid by fluid being imbibed into compartment 13 in a tendency towardsosmotic equilibrium at a rate controlled by the permeability of laminate12 and the osmotic pressure gradient across laminate 12 to continuouslydissolve agent 16 which is osmotically pumped from system 10 throughpassageway 15 at a controlled and continuous rate over a prolongedperiod of time. System 10, in another embodiment, releases agent 16 thathas limited solubility in the fluid and is mixed with an osmoticallyeffective compound by fluid being imbibed through laminate 12 intocompartment 13 in a tendency towards osmotic equilibrium at a ratecontrolled by the permeability of laminate 12 and the osmotic gradientacross laminate 12 to continuously dissolve the osmotically effectivecompound to form a solution containing agent which is pumped from system10 through passageway 15 at a controlled and continuous rate over aprolonged period of time.

System 10 of FIGS. 1A, 1B and 1C can be made into many embodimentsincluding the presently preferred embodiment for oral use, that is, forreleasing in the gastrointestinal tract either a locally or systemicallyacting therapeutic agent over a prolonged period of time. Oral system 10can have various conventional shapes and sizes such as round with adiameter of 3/16 inch to 1/2 inch, or it can be shaped like a capsulehaving a range of sizes from triple zero to zero, and from 1 to 8.

FIG. 2 represents another system 10 manufactured according to theinvention and designed for administering drug. In FIG. 2, system 10 ismounted on a drug receptor site 21, an arm of a human, for administeringdrug locally or systemically by absorption or drug penetration. System10 is comprised of a non-toxic, laminate 12 surrounding and forming ahalf-circle shaped compartment, interior not shown, that contains anagent, or optionally a mixture of an agent and an osmotically effectivecompound. Laminate 12 is provided with a base ring 22 having a curvaturethat corresponds to the curvature of site 21 for securing system 10 tosite 21. System 10 has a passageway positioned on its under surface, notshown, for releasing drug to site 21. Laminate 12 forms the undersurface of system 10, which under surface is made of a semipermeablelaminae forming material that is partially coated on its outer perimeterat base ring 22 with a thin layer of a non-toxic dermal-binding adhesivefor holding system 10 on site 21. Moisture is drawn in from the bodythrough semipermeable laminate 12. The half-circled surface of laminate12 is made of a material that is substantially impermeable to fluid andsubstantially impermeable to agent to prevent loss of moisture thatenters the compartment through the semipermeable laminated surface, andalso to insure that all the agent is released through the passageway tosite 21. System 10 is structured and operates as previously describedand it administers drug at a controlled and continuous rate to site 21for a prolonged period of time.

FIG. 3 shows an osmotic system 10 designed for placement in a vagina.System 10 has an elongated, cylindrical, self-sustaining shape with arounded lead end 23 and it is equipped with a manually controlled cord24 for easily removing system 10 from a vagina. System 10 isstructurally identical with system 10 as described above and it alsooperates in a like manner. System 10 of FIG. 3 in one embodimentcontains a drug designed for absorption by the vaginal mucosa to producea local or systemic effect, and in another embodiment, it contains anodor reductant that emits an odor counteracting scent or fragrence inthe vagina.

Referring to FIG. 4, an ocular therapeutic system 10 is seen in an eye25 for administering drug at an osmotically metered dosage rate thereto.In FIG. 4, eye 25 is comprised of an upper eyelid 26 with eyelashes 27and lower eyelid 28 with eyelashs 29. Eye 25 anatomically is comprisedof an eyeball 30 covered for the greater part by sclera 31 and at itscenter area by cornea 32. Eyelids 26 and 28 are lined with an epithelialmembrane or palpebral conjuctiva, and sclera 31 is lined with a bulbarconjunctiva that covers the exposed surface of eyeball 30. Cornea 32 iscovered with a transparent epithelial membrane. The portion of thepalpebral conjunctiva which lines upper eyelid 26 and the underlyingportion of the bulbar conjunctiva defines an upper cul-de-sac, whilethat portion of the palpebral conjunctiva which lines lower eyelid 28and the underlying portion of the bulbar conjunctiva defines a lowercul-de-sac. Ocular, osmotic system 10, seen in broken lines, is designedfor placement in the upper or lower cul-de-sac. System 10 is seen in thelower cul-de-sac and it is held in place by the natural pressure oflower eyelid 28. System 10 contains an ophthalmic drug for release toeye 25 at a controlled and continuous rate over a prolonged period oftime.

Ocular system 10 can have any geometric shape that fits comfortably inthe cul-de-sac. Typical shapes include ellipsoid, bean, banana,circular, rectangular, doughnut, crescent and half-ring shaped devices.In cross-section, the devices can be doubly convex, concavo-convex,rectangular and the like, as the device in use will tend to conform tothe shape of the eye. The dimensions of an ocular system can vary widelywith the lower limit governed by the amount of drug to be supplied tothe eye as well as by the smallest sized system that can be placed intothe eye. The upper limit on the size of the system is governed by thespace limitation in the eye consistent with comfortable retention in theeye. Satisfactory systems have a length of 4 to 20 millimeters, a widthof 1 to 15 millimeters. The ocular system can contain from 0.15micrograms to 100 milligrams of drug, or more, and it is made frommaterials non-toxic to the eye.

While FIGS. 1 through 4 are illustrative of various systems that can bemade according to the invention, it is to be understood these systemsare not to be construed as limiting, as the systems can take a widevariety of shapes, sizes and forms for delivering agent to differentenvironments of use. For example, the systems include buccal, implant,anal, artificial gland, cervical, intrauterine, rectal, and ear systems.The systems also can be adapted for delivering an active agent instreams, aquariums, fields, factories, reservoirs, laboratoryfacilities, hot houses, transportation means, navel means, air andmilitary means, hospitals, veterinary clinics, nursing homes, chemicalreactions, and other environments of use.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the practice of the invention, it has now been foundthat osmotic delivery system 10 can be manufactured with a laminate(s)12 comprised of at least two different laminae selected from the groupof materials known as semipermeable, osmosis and reverse osmosismaterials. The phrases "inert lamina forming material" and "unit orsingle semipermeable polymeric lamina forming material" as used for thepresent purpose means that each lamina is formed of a homopolymer or acopolymer. Laminae 19 and 20, or both in one embodiment areindependently selected from semipermeable polymers which genericallyinclude lamina forming polysaccharides comprised of anhydroglucoseunits. In one embodiment, the polysaccharides are cellulose estershaving a degree of substitution, D.S., on the anhydroglucose unit fromgreater than 0 up to 3 inclusive. By "degree of substitution" as usedherein is meant the average number of hydroxyl groups on theanhydroglucose unit of the polymer replaced by a substituting group.Exemplary materials are represented by Formula 1: ##STR1## wherein R₁,R₂ and R₃ are the same or different and they are selected from the groupconsisting of hydrogen and acyl, ##STR2## with at least one or all ofR₁, R₂ and R₃ in the anhydroglucose unit either partially or completelysubstituted with the acyl moiety. The acyl moiety at R₁, R₂ and R₃ canbe the same or different; and, R₄ is a member selected from the groupconsisting of hydrogen, alkyl groups of the straight or branched chaintype having from 1 to 20 carbons and alkenyl groups that are straight orbranched and have from 2 to 20 carbon atoms. Typical acyl moietiesinclude alkanoyl and alkenoyl such as formyl, acetyl, propionyl,butyryl, hexanoyl, heptanoyl, octanoyl, undecanoyl, lauroyl, palmitoyl,stearoyl, oleoyl, and isomeric forms thereof; an n in a presentlypreferred embodiment is a positive number greater than 5.

Representative materials embraced by Formula 1 include polymericcellulose esters such as mono, di, and tricellulose acylates. Exemplarypolymers include cellulose acetate having a D.S. of 1 and an acetylcontent of up to 21%; cellulose diacetate having a D.S. of 2 and anacetyl content of 21 to 35%; cellulose triacetate having a D.S. of 3 andan acetyl content of 35 to 44.8%; cellulose propionate having a D.S. of1.8 and a propionyl content of 38.5%; cellulose acetate propionatehaving an acetyl content of 1.5 to 7% and a propionyl content of 39 to42%; cellulose acetate propionate having an acetyl content of 2.5 to 3%,an average combined propionyl content of 39.2 to 45% and a hydroxylcontent of 2.8 to 5.4%; cellulose acetate butyrate having a D.S. of 1.8,an acetyl content of 13 to 15%, and a butyryl content of 34 to 39 %;cellulose acetate butyrate having an acetyl content of 2 to 29.5%, abutyryl content of 17 to 53%, and a hydroxyl content of 0.5 to 4.7%;cellulose triacylates having a D.S. of 2.9 to 3 such as cellulosetrivalerate, cellulose trilaurate, cellulose tripalmitate, cellulosetrisuccinate, cellulose triheptylate, cellulose tricaprylate, cellulosetrioctanoate and cellulose tripropionate; cellulose diesters having alower degree of substitution and prepared by the hydrolysis of thecorresponding triester to yield cellulose diacylates having a D.S. of2.2 to 2.6 such as cellulose disuccinate, cellulose dipalmitate,cellulose dioctanoate, cellulose dicaprylate and cellulose dipentanoateand esters prepared from acyl anhydrides or acyl acids in anesterification reaction to yield esters containing acyl attached to thesame cellulose polymer such as cellulose acetate valerate, celluloseacetate succinate, cellulose propionate succinate, cellulose acetateoctanoate, cellulose valerate palmitate, cellulose acetate palmitate andcellulose acetate heptanoate. Generally, the laminae useful for formingthe laminate wall will have a fluid permeability of 10⁻⁵ to 10⁻¹(cc·mil/cm² ·hr·atm), expressed per atmosphere of hydrostatic or osmoticpressure difference across the lamina at the temperature of use whilepossessing a high degree of impermeability to solute are useful for thepurpose of the invention. The polymers described above are known to theart or they can be prepared according to the procedures in Encyclopediaof Polymer Science and Technology, Vol. 3, pages 325 to 354, 1964,published by Interscience Publishers Inc., New York.

Laminae 19 or 20 or both also can be independently selected fromdifferent unit materials embraced by Formula 2 as follows: ##STR3##wherein R₅ is a member selected from the group consisting of hydroxyl;alkoxy; alkoxy substituted with a member selected from the groupconsisting of alkyl, alkoxy, halogen and cyano; alkylcarbonate;alkylcarbamate; alkylsulfonate; alkylsulfamate; oxalkyleneoxycarboalkyl;acyloxy including alkanoyloxy, alkenoyloxy and aroyloxy; alkanoyloxysubstituted with an alkoxy, halogen, carboalkyl, carboalkoxy andcyanoalkoxy; aroyloxy substituted with a halo, carboxy, carboalkyl andcyano; furoyloxy, and n is a positive integer greater than 5, usually 10to 3 × 10⁶.

Exemplary groups representative of R₅ of Formula 2 are as follows: by"alkyl" is meant straight or branched chain alkyl radicals of 1 to 20carbon atoms inclusive, such as methyl, ethyl, n-propyl, iso-propyl,n-butyl, sec-butyl, pentyl, neo-pentyl, n-hexyl, iso-hexyl, heptyl,4,4-dimethyl pentyl, 2,2,4-trimethylpentyl, and nonyl. By "alkenyl" ismeant straight or branched chain alkenyl groups of 2 to 20 carbons suchas 1-propenyl, 2-propenyl or allyl, 1-butenyl, 2-butenyl, 1-pentenyl,and the corresponding positional isomers such as 1-isobutenyl,2-isobutenyl, 2-sec-butenyl, 2-methyl-1-butenyl, 2-methyl-2-pentyenyland 2,3-dimethyl-3-hexenyl. The term "alkoxy" as used for R₅ includedthe straight and branched chain alkoxy groups having 1 to 20 carbonsinclusive, for example, methoxy, ethoxy, propoxy, butoxy, n-pentoxy,n-hexoxy, isopropoxy, 2-butoxy, isobutoxy, 3-pentoxy, and n-octoxy.Exemplary halogen include fluorine, chlorine and bromine. Exemplary arylinclude phenyl and naphthyl. Representative alkylene as a linking moietywithin a substituent are alkylene of 2 to 10 carbons such as1,2-ethylene, 1,3-propylene, 1,2-propylene, 1,4-butylene, 1,5-pentylene,1,6-hexylene, 1,7-heptylene and 1,10-decylene. Exemplary alkanoyloxy,alkenoyloxy and aroyloxy include formyloxy, acetyloxy, propionyloxy,valeryloxy, heptanoyloxy, octanoyloxy, undecanoyloxy, lauroyloxy,palmitoyloxy, stearoyloxy, oleoyloxy, acryloyloxy, methacryloyloxy,crotomyloxy, 3-butenoyloxy, benzoyloxy, phenylacetyloxy, cinnamoyloxy,naphthoyloxy, p-ethoxybenzyloxy, alloxyphenylacetyloxy, furoyloxy,p-nitrobenzoyloxy and chlorophenoxyacetyloxy.

The lamina forming materials embraced by Formula 2 includepolysaccharide materials having a degree of substitution on theanhydroglucose unit greater than from 0 up to 3 inclusive with thesubstituents at R₅ the same or different and bonded to a common mer. Thematerials can be polymeric cellulose esters or polymeric celluloseethers. The monomeric unit can be substituted with like ester groups,with different ester groups, with like ether groups, with differentether groups and with different ester and ether groups bonded to thesame polymer to give a homopolymer or copolymer. Typical materialsrepresented by Formula 2 include cellulose acetate acetoacetate,cellulose acetate chloroacetate, cellulose acetate furoate,dimethoxyethylcellulose acetate, cellulose acetatecarboxymethoxypropionate, cellulose acetate phthalate, cellulosebutyrate naphthylate, cellulose acetate benzoate, methylcelluloseacetate, methylcyanoethyl cellulose, cellulose acetate methoxyacetate,cellulose acetate, cellulose acetate ethoxyacetate, cellulose acetatedimethylsulfamate, ethylcellulose dimethylsulfamate, cellulose acetatep-toluene sulfonate, cellulose acetate methylsulfonate, celluloseacetate butylsulfonate, cellulose acetate dimethylaminoacetate,cellulose acetate ethyloxalate, cellulose resinate, cellulose acetatemethylcarbonate, cellulose acetate ethylcarbonate, cellulose acetatemethylcarbamate, and cellulose acetate ethylcarbamate.

The semipermeable laminae forming materials also include celluloseethers such as alkylcellulose, methylcellulose, ethylcellulose,ethylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,hydroxyethyl methylcellulose, hydroxypropyl methylcellulose,ethylhydroxy ethylcellulose, hydroxybutyl methylcellulose,cyanoethylcellulose, benzylcellulose, sodium carboxymethylcellulose,sodium carboxymethylhydroxy ethylcellulose, carbamoylethylcellulose,carboxyethylcellulose, phenylcellulose, benzylhydrylcellulose,tritylcellulose, hexylpropylcellulose, carboxylbenzyl cellulose, and2-carboxylbenzoyloxy propylcellulose. Methods for preparing thecellulose ethers are disclosed in Encyclopedia of Polymer Science andTechnology, Vol. 3, pages 459 to 549, 1964, published by IntersciencePublishers, Inc., New York.

Other semipermeable materials include acylated polysaccharides andacylated starches such as agar-agar acetate, acylated alginates, amylosetriacetate, beta glucan acetate, beta glucan triacetate, acetylalginate, triacetate of locust bean gum, alkanoyl carrageenin, acylatedtragacanth, esterified gum karaya, cellulose derivatives substitutedwith an inorganic moiety such as a nitro group, hydroxylated ethylenevinylacetate, aromatic nitrogen containing polymeric materials thatexhibit permeability to aqueous fluids and substantially no passage tosolute, semipermeable membranes made from polymeric epoxides, copolymersof alkylene oxides and alkyl glycidyl ethers, polyvinyl acetate,cross-linked polyvinyl acetate, polyurethanes, film forming materials asdisclosed by Loeb and Sourirajan in U.S. Pat. No. 3,133,132,cross-linked derivatives of polyvinyl alcohol, polyvinyl butyrate,ionically associated polyelectrolytes formed by the coprecipitation of apolycation and a polyanion as described in U.S. Pat. Nos. 3,276,586;3,541,005; 3,541,006; 3,546,142; and 3,173,876; polystyrene derivativessuch as poly(sodium styrene sulfonate) and poly(vinylbenzyltrimethylammonium chloride), polyesters, polyamides and polyacrylates. Thesesemipermeable materials and other semipermeable materials are known tothe art and disclosed in Handbook of Common Polymers by Scott, J. R. andRoff, W. J., 1971, published by CRC Press, Cleveland, Ohio.

Suitable laminae forming materials for manufacturing an osmotic systemcan be selected from the above materials according to the criteriondisclosed in U.S. Pat. Nos. 3,845,770 and 3,916,899. This criterionconsists in first calculating for a laminate that is to be selected, thepermeability to fluid necessary to deliver an amount of agent Q_(p), inmg, in time t, in hours, from a device having a total laminate area A,in cm², a laminate thickness h, in mils, with the agent having asolubility in the fluid S, in mg/ml (solution), and the agent having anosmotic pressure in the device of π, in atm. The value k is expressed inunits (cm³ /cm²) · (mil/hr·atm), and it is calculated from Equation 1.

    k = h/S A · .sup.Q p/t · 1/π          (1)

Then, after having calculated the desired laminate permeability k fromEquation 1, laboratory measurements are made to identify laminaematerials capable of forming a laminate having a permeability k_(o)substantially equivalent to the calculated permeability k. Themeasurements are carried out by using a standard osmosis cell andmeasuring the rate of fluid flow through a laminate made of laminaeforming materials having a known composition and thickness. The flowrate is determined by measuring fluid transport from a first chambercontaining a fluid free of agent through a laminate that separates itfrom a second chamber housing a solution containing a knownconcentration of agent that exhibits an osmotic gradient across thelaminate. Sometimes the chamber contains an osmotically effectivecompound which is used as osmotic driving agent in the final device. Theflow measurement is performed by adding to the first chamber the fluidand then adding to the second chamber, equipped with a stirring bar, thesame fluid containing agent, and optionally containing the additionalosmotic agents. The first chamber is connected through a conduit to areservoir containing a supply of fluid and the second chamber isconnected to a vertically positioned tube of known diameter andcalibrated with indicia that indicate the amount of fluid in the tube.In operation, fluid flows from the first chamber through the laminateinto the second chamber by osmosis causing the solution to rise in thetube over time, t, to give a volume displacement, ΔV, during a timeinterval, Δt. The volume, ΔV, is read on the tube calibrated in cm³, andthe time interval, Δt, is measured with a stopwatch. The value k_(o)π_(o) in cm³ ·mil/cm² ·hr for the laminate with permeability, k_(o), forthe agent solution with an osmotic pressure, π_(o), is calculated fromEquation 2, and wherein A_(o) is the area of the membrane, in thediffusion cell, and h_(o) is the thickness of this membrane.

    k.sub.o π.sub.o = ΔV/Δt · h.sub.o /A.sub.o (2)

If the measured value, k_(o), approximates the calculated value, k, thelaminate can be used for manufacturing the osmotic device. Otherprocedures and devices useful for measuring fluid permeability andosmotic flow are disclosed in J. App. Poly. Sci., Vol. 9, pages 1341 to1362, 1965; and in Yale J. Biol. Med., Vol. 42, pages 139 to 153, 1970.

The physical and chemical integrity and the inertness of the abovematerials can be ascertained by those skilled in the art by using theprocedures described below. These procedures are the lamina weight lossand the osmosis procedures. The weight loss procedure is carried outwith a lamina that is cast from solution or optionally melt pressed. Thelamina is solution cast with a Gardner film-casting knife on a cleanglass plate at room temperature with the solution removed by evaporationin an oven at elevated temperatures until the lamina is dry. Next, thelamina is removed from the glass and cut into strips 1 to 10 cm inlength, 1 to 10 cm in width and having a thickness of 1 to 10 mils.Then, after all the strips are cut to have the same area and weight,they are placed in a glass container filled with a solution consistingof a known concentration of agent formulated with the fluid of theenvironment of use. The temperature of the container is made tocorrespond to the temperature of the environment where an osmotic systemformed with the lamina will be placed for releasing agents. At regulartime intervals, strips are taken form the solution, rinsed in distilledwater, dried in an oven, usually 50° C for 24 hours, and weighed. Theweight of a single strip repeatedly introduced into the solution, or theweight of many strips consecutively removed at different time intervalsare indicated along the ordinate, plotted as a function of timeindicated along the abscissa, such as t₁, t₂, t₃, etc. as shown in FIG.5. In FIG. 5, line 1 represents the results obtained for a lamina thatmaintains its physical and chemical integrity when exposed to agentsolution. That is, the lamina does not lose any weight over time anddemonstrates inertness in the presence of agent solution. In the samefigure, line 2 represents a lamina which upon exposure to agentsolution, demonstrates a weight loss and is undesirable for making anosmotic system.

In the osmosis procedure, the rate of fluid flow through a laminate ismeasured and it is performed using an osmosis cell. The purpose of theprocedure is to ascertain, (1) if a given laminate maintains itsintegrity in the presence of fluid and agent. The procedure is carriedout using the cell according to the above described procedure with thevolume of solution, ΔV, rising in the tube attached to chamber 2measured and plotted as a function of time, t. The data obtained for twodifferent laminates are shown in FIG. 6. In FIG. 6, line 1 represents alaminate that maintains its integrity in the presence of fluid andagent. That is, since the rate of fluid flow is substantially constant,the laminate does not undergo any substantial change over time, t. Line2 shows the fluid flux, ΔV/Δt, through a laminate where the rate iscontinually increasing over time. This change indicates the laminatedoes not maintain its integrity in the presence of fluid and agent. Forthose applications where a change in flux is unwanted, a differentlaminate should be selected for the system. Using the above techniques,one versed in the art would use the weight loss and osmosis proceduresfor deciding if the fluid and agent adversely effect the laminate andfor determining if a laminate is suited for a particular application.This procedure also can be used to ascertain the properties of laminae.

Additional scientific criterions that can be used by those skilled inthe art for selecting laminate materials that have increased inertness,include the following: (a) the polymeric materials forming the laminaeof the laminate have a high degree of substitution, for example, thematerials have undergone etherification or esterification particularlyacylation towards or to completion with the laminae demonstratingincreased resistance to hydrolysis and increased rejection of agent, (b)the laminae of the laminate exhibits a flux decrease with increasingmolecular size of the substituting groups, such as an ether or estergroup, (c) the laminae of the laminate exhibits a flux decreaseproportional to the increase in size of the substituents, for example,the decrease occurs as the number of carbon atoms increase in ahydrocarbon moiety such as an alkyl or alkoxy moiety, (d) the laminae ofthe laminate exhibits increased stability with an increase in the degreeor substitution of hydrophobic ether and larger hydrophobic ester groupswith an accompanying decrease in the degree of substitution of smallerhydrophilic ester groups, and (e) the laminae of the laminate exhibits aflux decrease as the number of polar, ionic groups decrease. J. App.Poly. Sci., Vol. 9, pages 1341 to 1362, 1965.

The expression "passageway" as used herein comprises means and methodssuitable for releasing the agent from the system. The expressionincludes an aperture, orifice or bore through the laminate formed bymechanical procedures, or by eroding an erodible element, such as agelatin plug, in the environment of use. A detailed description ofosmotic passageways and the maximum and minimum dimensions for apassageway are disclosed in U.S. Pat. No. 3,845,770 and in U.S. pat. No.3,916,899.

The osmotically effective compounds that can be used for the purpose ofthe invention include inorganic and organic compounds that exhibit anosmotic pressure gradient against an external fluid across laminate 12of the device. The compounds, also known as osmagents, are mixed with anagent that has limited solubility in the external fluid with thecompound forming a saturated solution containing agent that isosmotically delivered from the device. The phrase "limited solubility"as used herein means the agent has a solubility of about less than 1% byweight in the external fluid. The compounds are used by homogeneously orheterogenously mixing the compound or a mixture of compounds with anagent, either before they are charged into the reservoir, or byself-mixing after they are charged into the reservoir. In operation,these compounds attract fluid into the device producing a solution ofcompound which is delivered from the device concomitantly transportingundissolved and dissolved agent to the exterior of the device.Osmotically effective compounds useful for the present purpose includemagnesium sulfate, magnesium chloride, sodium chloride, lithiumchloride, potassium sulfate, sodium carbonate, sodium sulfite, lithiumsulfate, potassium chloride, calcium bicarbonate, sodium sulfate,calcium sulfate, potassium acid phosphate, calcium lactate, d-mannitol,urea, inositol, magnesium succinate, tartaric acid, carbohydrates suchas raffinose, sucrose, glucose, α-d-lactose monohydrate, and mixturesthereof. The compound is initially present in excess and it can be inany physical form such as particle, crystal, pellet, tablet, strip, filmor granule. The osmotic pressure of saturated solutions of variousosmotically effective compounds and for mixtures of compounds at 37° C,in water, is listed in Table 1. In the table, the osmotic pressure π, isin atmospheres, ATM. The osmotic pressure is measured in a commerciallyavailable osmometer that measures the vapor pressure difference betweenpure water and the solution to be analyzed, and according to standardthermodynamic principles, the vapor pressure difference is convertedinto osmotic pressure. In Table 1, osmotic pressures of from 20 ATM to500 ATM are set forth; of course, the invention includes the use oflower osmotic pressures from zero, and higher osmotic pressures thanthose set forth by way of example in Table 1. The osmometer used for thepresent measurements is identified as Model 302B, Vapor PressureOsmometer, manufactured by the Hewlett Packard Co., Avondale, Penna.

                  TABLE 1                                                         ______________________________________                                        COMPOUND OR          OSMOTIC PRESSURE                                          MIXTURE             ATM                                                      ______________________________________                                        Lactose-Fructose     500                                                      Dextrose-Fructose    450                                                      Sucrose-Fructose     430                                                      Mannitol-Fructose    415                                                      Sodium Chloride      356                                                      Fructose             355                                                      Lactose-Sucrose      250                                                      Potassium Chloride   245                                                      Lactose-Dextrose     225                                                      Mannitol-Dextrose    225                                                      Dextrose-Sucrose     190                                                      Mannitol-Sucrose     170                                                      Sucrose              150                                                      Mannitol-Lactose     130                                                      Dextrose              82                                                      Potassium Sulfate     39                                                      Mannitol              38                                                      Sodium Phosphate Tribasic . 12H.sub.2 O                                                             36                                                      Sodium Phosphate Dibasic . 7H.sub.2 O                                                               31                                                      Sodium Phosphate Dibasic . 12H.sub.2 O                                                              31                                                      Sodium Phosphate Dibasic Anhydrous                                                                  29                                                      Sodium Phosphate Monobasic . H.sub.2 O                                                              28                                                      ______________________________________                                    

The expression "active agent" as used herein broadly includes anycompound, composition of matter or mixture thereof, that can bedelivered from the system to produce a beneficial and useful result. Theagent can be soluble in a fluid that enters the compartment andfunctions as an osmotically effective solute or it can have limitedsolubility in the fluid and be mixed with an osmotically effectivecompound soluble in fluid that is delivered from the system. The activeagent includes pesticides, herbicides, germicides, biocides, algicides,rodenticides, fungicides, insecticides, anti-oxidants, plant growthpromoters, plant growth inhibitors, preservatives, disinfectants,sterilization agents, catalysts, chemical reactants, fermentationagents, foods, food supplements, nutrients, cosmetics, drugs, vitamins,sex sterilants, fertility inhibitors, fertility promoters, airpurifiers, micro-organism attenuators, and other agents that benefit theenvironment of use.

In the specification and the accompanying claims, the term "drug"includes any physiologically or pharmacologically active substance thatproduces a localized or systemic effect or effects in animals, includingmammals, humans and primates, avians, domestic household, sport or farmanimals such as sheep, goats, cattle, horses and pigs, for administeringto laboratory animals such as mice, rats and guinea pigs, and to fishes,reptiles and zoo animals. The active drug that can be delivered includesinorganic and organic compounds without limitation, those materials thatact on the central nervous system such as hypnotics and sedatives,including pentobarbital sodium, phenobarbital, secobarbital, thiopentaland mixtures thereof, heterocyclic hypnotics such as dioxopiperidinesand glutarimides, hypnotics and sedatives such as amides and ureas,exemplified by diethylisovaleramide and α-bromoisovaleryl urea, hypnoticand sedative urethanes and disulfanes, psychic energizers such asisocarboxazid, nialamide, phenelzine, imipramine, tranylcypromine andpargylene, tranquilizers such as chloropromazine, promazine,fluphenazine, reserpine, deserpidine, meprobamate, benzodiazepines suchas chlordiazepoxide, anticonvulsants such as primidone, enitabas,diphenylhydantoin, ethltion, pheneturide and ethosuximide, musclerelaxants and antiparkinson agents such as mephenesin, methocarbomal,trihexylphenidyl, biperiden, levo-dopa also known as L-dopa andL-β-3-4-dihydroxypehnylalanine, analgesics such as morphone, codeine,meperidine, nalorphine, antipyretics and anti-inflammatory agents suchas aspirin, salicylamide, colchicine and sodium salicylamide, localanesthetics such as procaine, lidocaine, naepaine, piperocaine,tetracaine and dibucane, antispasmodics and muscle contractants such asatropine, scopolamine, methscopolamine, oxyphenonium, papaverine,prostaglandins such as PGE₁, PGE₂, PGF₁α PGF₂α and PGA, anti-microbialssuch as penicillin, tetracycline, oxytetracycline, chlorotetracycline,chloramphenicol and sulfonamides, anti-malarials such as4-aminoquinolines, 8-aminoquinolines and pyrimethamine, hormonal agentssuch as prednisolone, cortisone, cortisol and triamcinolone, androgenicsteroids such as methyltestosterone, and fluoxmesterone, estrogenicsteroids such as 17β-estradiol, α-estradiol, estriol, α-estradiol3-benzoate, and 17-ethynyl estradiol-3-methyl ether, progestationalsteriods such as progesterone, 19-nor-pregn- 4-ene-3,20-dione,17-hydroxy-19-nor-17-α-pregn-5(10)-ene-20-yn-3-one, 17α-ethynyl-17-hydroxy-5(10)-estren-3-one, and 9β,10α-pregna-4,6-diene-3,20-dione, sympathomimetic drugs such asepinephrine, amphetamine, ephedrine and norepinephrine, cardiovasculardrugs such as procainamide, procainamide sulfate, procainamidehydrochloride, procainaminde salts, amyl nitrile, nitroglycerin,dipyredamole, sodium nitrate and mannitol nitrate, diuretics such aschlorathiazide, acetazolamide, methazolamide and flumethiazide,antiparasitics such as bephenium, hydroxynaphthoate, dichlorophen anddapsone, neoplastics such as mechlorethamine, uracil mustard,5-fluorouracil, 6-thioguanine and procarbazine, hypoglycemic drugs suchas insulin, isophane insulin, protamine zinc insulin suspension, globinzinc insulin, extended insulin zinc suspension, tolbutamide,acetohexamide, tolazamide and chlorpropamide, nutritional agents such asascorbic acid, niacin, nicotinamide, folic acid, choline, biotin,pantothenic acid, and vitamin B₁₂, essential amino acids, essentialfats, eye drugs such as pilocarpine, pilocarpine salts such aspilocarpine nitrate, pilocarpine hydrochloride, dichlorphenamide,atropine, atropine sulfate, scopolamine and eserine salicylate, andelectrolytes such as calcium gluconate, calcium lactate, potassiumchloride, potassium sulfate, sodium chloride, potassium fluoride,ferrous lactate, ferrous gluconate, ferrous sulfate, ferrous fumurateand sodium lactate. The beneficial drugs are known to the art inPharmaceutical Sciences, by Remington, 14th Ed., 1970, published by MackPublishing Co., Easton, Penna.; and in The Pharmacological Basis ofTherapeutics, by Goodman and Gilman, 4th Ed., 1970, published by TheMacMillian Company, London.

The drug can also be in various forms, such as uncharged molecules,molecular complexes, pharmacologically acceptable salts such ashydrochlorides, hydrobromides, sulfate, laurylate, palmitate, phosphate,nitrate, borate, acetate, maleate, tartrate, oleate, and salicylate. Foracidic drugs, salts of metals, amines or organic cations, for examplequaternary ammonium can be used. Derivatives of drugs such as esters,ethers and amides which have solubility characteristics suitable for useherein can be used alone or mixed with other drugs. Also, a drug that iswater insoluble can be used in a form that is a water soluble derivativethereof to effectively serve as a solute, and on its release from thedevice, is converted by enzymes, hydrolyzed by body pH or othermetabolic processes to the original form, or to a biologically activeform. The agent can be in the reservoir as a solution, dispersion,paste, cream, particle, granule, emulsion, suspension or powder. Also,the agent can be mixed with a binder, dispersant, emulsifier or wettingagent and dyes.

The amount of agent present in the system is initially in excess of theamount that can be dissolved in the fluid that enters the compartment.Under this physical state when the agent is in excess, the system willosmotically operate to give a substantially constant rate of release.The rate of agent release pattern can also be varied by having differentamounts of agent in the reservoir to form solutions containing differentconcentrations of agent for delivery from the system. Generally, thesystem can house from 0.05 ng to 5 grams or more, with individualsystems containing for example, 25 ng, 1 mg, 5 mg, 250 mg, 500 mg, 1.5g, and the like.

The solubility of an agent in an external fluid can be determined byvarious art known techniques. One method consists in preparing asaturated solution comprising the external fluid plus the agent asascertained by analyzing the amount of agent present in a definitequantity of the fluid. A simple apparatus for this purpose consists of atest tube of medium size fastened upright in a water bath maintained atconstant temperature and pressure, for example, one atmosphere, in whichthe fluid and agent are placed and stirred by a motor driven rotatingglass spiral. After a given period of stirring, a definite weight of thefluid is analyzed and the stirring continued for an additional period oftime. If the analysis shows no increase of dissolved agent aftersuccessive periods of stirring, in the presence of excess solid agent inthe fluid, the solution is saturated and the results are taken as thesolubility of the product in the fluid. If the agent is soluble andadded osmotically effective compound is not needed; if the agent haslimited solubility in the fluid, then an osmotically effective compoundcan be incorporated into the device. Numerous other methods areavailable for the determination of the solubility of an agent in afluid. Typical methods used for the measurement of solubility arechemical analysis, ultra violet spectometry, density, refractive indexand electrical conductivity. Details of various methods for determiningsolubilities are described in United States Public Health ServiceBulletin, No. 67 of the Hygienic Laboratory; Encyclopedia of Science andTechnology, Vol. 12, pages 542 to 556, 1971, published by McGraw-Hill,Inc.; and Encyclopaedic Dictionary of Physics, Vol. 6, pages 547 to 557,1962, published by Pergamon Press, Inc.

The systems of the invention are manufactured by standard techniques.For example, in one embodiment, the agent and other ingredients that maybe housed in the compartment and a solvent are mixed into a solid,semisolid or gel form by conventional methods such as ballmilling,calendering, stirring, or rollmilling and then pressed into apreselected shape. The laminate forming the system can be applied bymolding, spraying or dipping the pressed shape into the materials. Inanother embodiment, laminae can be cast into films, shaped to thedesired dimensions, an exterior lamina sealed to an interior lamina todefine a laminate that surrounds a compartment that is filled with agentand then closed. The system also can be manufactured with an emptycompartment that is filled through the passageway. The laminae formingthe laminate can be joined by various joining techniques such as highfrequency electronic sealing that provides clean edges and firmly formedlaminates. Another, and presently preferred, technique that can be usedis the air suspension procedure. This procedure consists in suspendingand tumbling the agent in a current of air and a lamina compositionuntil the lamina is applied to the agent. The procedure is repeated witha different lamina to form the laminate. The air suspension procedure isdescribed in U.S. Pat. No. 2,799,241; J. Am. Pharm. Assoc., Vol. 48,pages 451 to 459, 1959; and ibid., Vol. 49, pages 82 to 84, 1960. Otherlamina forming techniques such as pan coating can be used in which thelaminae are deposited by successive spraying of the polymer solutionwith the agent tumbling in the rotating pan. Other standardmanufacturing procedures are described in Modern Plastics Encyclopedia,Vol. 46, pages 62 to 70, 1969; and in Pharmaceutical Sciences, byRemington, Fourteenth Edition, pages 1626 to 1678, 1970, published byMack Publishing Company, Easton, Penna.

Exemplary solvents suitable for manufacturing the laminated wall includeinert inorganic and organic solvents that do not adversely harm the wallforming materials and the final laminate. The solvents broadly includemembers selected from the group consisting of aqueous solvents,alcohols, ketones, esters, ethers, aliphatic hydrocarbons, halogenatedsolvents, cycloaliphatic, aromatics heterocyclic solvents and mixturesthereof. Typical solvents include acetone, diacetone alcohol, methanol,ethanol, isopropyl alcohol, butyl alcohol, methyl acetate, ethylacetate, isopropyl alcohol, butyl alcohol, methyl acetate, ethylacetate, isopropyl acetate, n-butyl acetate, methyl isobutyl ketone,methyl propyl ketone, n-hexane, n-heptane, ethylene glycol monoethylether, ethylene glycol monoethyl acetate, methylene dichloride, ethylenedichloride, propylene dichloride, carbon tetrachloride, nitroethane,nitropropane, tetrachloroethane, ethyl ether, isopropyl ether,cyclohexane, cyclooctane, benzene, toluene, naphtha, 1,4-dioxane,tetrahydrofuran, diglyme, water, and mixtures thereof such as acetoneand water, acetone and methanol, acetone and ethyl alcohol, methylenedichloride and methanol, and ethylene dichloride and methanol.

The following examples are merely illustrative of the present inventionand they should not be considered as limiting the scope of the inventionin any way, as these examples and other equivalents thereof will becomeapparent to those versed in the art in the light of the presentdisclosure, the drawing and the accompanying claims.

EXAMPLE 1

An osmotic, ocular therapeutic system for the controlled and continuousdelivery of pilocarpine nitrate at a rate of 105 μg/hr from a systemhaving a unit, laminated wall with a total area of 1.2 cm² and alaminate thickness of 3 mils, with the pilocarpine nitrate having asolubility of 250 mg/ml in water, and with the ocular system designed inthe form of an elliptical shaped system is constructed as follows:first, to an elliptical shaped drug core consisting of pilocarpinenitrate is applied, from dimethyl formamide solvent, a 1 mil thick, h₁,lamina of inert, ophthalmologically acceptable semipermeablepolyurethane to yield an inner lamina having a kπ₁ of 0.36 × 10⁻³cc·mil/hr·cm². Next, to the total outer surface of the polyurethanelamina is applied, in laminar contacting relation, from a 5% polymersolution in acetone:water in the ratio of 90:10, a 2 mil thick, h₂,lamina of inert, ophthalmologically acceptable semipermeable celluloseacetate having an acetyl content of 32% to yield a lamina that forms anintegral unit laminate with the polyurethane lamina. The celluloseacetate lamina had a measured kπ₂ of 0.03 cc·mil/hr·cm². Finally, anosmotic passageway is drilled through the laminate for osmoticallyreleasing ophthalmic drug from the system. The passageway had a diameterof 2 mils.

The osmotic system releases a therapeutically effective amount ofpilocarpine nitrate according to relations 1 through 4 as follows:

    h.sub.T /kπ.sub.T = h.sub.1 /kπ.sub.1 + h.sub.2 /kπ.sub.2 (1)

wherein h_(T) is the total thickness of the laminate, h₁ is thethickness of the polyurethane lamina, h₂ is the thickness of thecellulose acetate lamina, kπ_(T) is the osmotic pressure of the drug inthe compartment of the system times the permeability of the laminate towater or eye fluid, and kπ₁ and kπ₂ represent the osmotic pressure ofthe drug in the compartment times the permeability of lamina₁ andlamina₂ to water or eye fluid respectively. ##EQU1##

    kπ.sub.T = 1.05 × 10.sup.-3 cc·mil/hr·cm.sup.2

The amount of drug delivered in μg/hr for the osmotic therapeutic systemis calculated as follows:

    dm/dt = S × A × Kπ.sub.T /h.sub.T           (3)

wherein S is the solubility of the drug in water or eye fluid and A isthe total area of the laminated wall in cm² : ##EQU2##

The osmotic system when placed in the cul-de-sac of an adult, human eyeadministers 105 μg/hr of pilocarpine nitrate with the system maintainingits uniformity and configuration during the osmotic dispensing period.

EXAMPLE 2

The ocular, osmotic therapeutic system described in Example 1 ismanufactured in this example with all conditions as previously describedexcept that the drug in the compartment is replaced with an ophthalmicdrug that is a member selected from the group consisting of idoxuridine,phenylephrine, pilocarpine, hydrochloride, eserine, carbachol,phospholine iodine, demecarium bromide, cyclopentolate, homatropine,scopolamine and epinephrine.

EXAMPLE 3

An osmotic therapeutic system manufactured in the form of an oral,osmotic device for releasing potassium chloride in the gastrointestinaltract was made as follows: first, 500 mgs of potassium chloride wascompressed by standard techniques with a 3/8 inch punch into acompressed mass having a total area of 2.3 cm². The mass was thenlaminated by surrounding it with a laminate comprised of an inner andouter laminae. The inner lamina was formed of non-erodible, inert 70minutes hydrolyzed polyvinyl acetate applied to the mass by the airsuspension techniques described in J. Pharm. Sci., Vol. 53, No. 8, pages877 to 881, 1964 and ibid., Vol. 53, No. 8, pages 953 to 955, 1964. A 5%polymer solution in 200 proof ethanol:water in the ratio of 90:10,volume to volume, was used to form the lamina which had a finalthickness h₁ of 1 mil and a kπ₁ of 0.1 cm.sup. 3 ·mil/cm² ·hr.

Next, an outer lamina that maintains its integrity in the environment ofuse and consisting of semipermeable polymeric cellulose acetate havingan acetyl content of 32% was laminated onto the total exposed surface oflamina h₁ to form a laminated wall that surrounded the potassiumchloride drug compartment. The cellulose acetate was intimately appliedto lamina h₁ from a 5% solution in acetone:water in the proportion of89:11, weight to weight. The outer lamina had a thickness h₂ of 3.6 milsand a kπ₂ of 0.27 cm³ ·mil/cm² ·hr.

The final laminated wall of the osmotic system had a thickness h_(T) of4.6 mils. An osmotic passageway was drilled through the laminated walland it had a diameter of 9 mils. The system had a controlled andcontinuous rate of release of 31.52 mgs/hr with a variation of about±5%. The rate of release was calculated according to relations 1 through4 as follows:

    h.sub.T /kπ.sub.T = h.sub.1 /kπ.sub.1 + h.sub.2 /kπ.sub.2 (1)

    4.6/kπ.sub.T = 1/0.1 + 3.6/0.27                         (2)

    kπ.sub.T = 0.197 cm.sup.3 ·mil/cm.sup.2 ·hr

    dm/dt = S × A × kπ.sub.T /h.sub.T           (3)

wherein S is the solubility of KCl in mg/ml at 37° C, and A is the totallaminated area exposed to the environment:

    dm/dt = 320 × 2.3 × 0.197/4.6                  (4)

    dm/dt = 31.52 mg/hr

EXAMPLE 4

A plurality of osmotic therapeutic systems are manufactured according tothe procedure of Example 3 wherein the conditions are as describedexcept that the drug of Example 3 was replaced with an orallyadministerable drug selected from the group consisting of methazolamide,ethoxyolamide, diazepam, amitriptylene hydrochloride, imipraminehydrochloride, naicin, benzthiazide, aminophylline, chlorothiazide,tolbutamide, tolazamide, chloropropamide, procainamide hydrochloride,colchicine and atropine.

EXAMPLE 5

An osmotic therapeutic system for delivering NaCl at an osmoticallycontrolled rate was manufactured according to the procedure of Examples1 and 3 with all conditions as previously described except that thelaminated wall surrounding the compartment comprised three lamina inintimate, total laminar arrangement to form a unit wall. In this system,the lamina facing the drug compartment consisted of polymeric celluloseacetate having an acetyl content of 38.3%, a thickness h₁ of 0.5 milsand a kπ₁ of 0.054 cc·mils/hr·cm². The lamina was formed from a 4%polymer solution in acetone. A section lamina h₂ consisting of polymericcellulose acetate having an acetyl content of 32.0% was laminated from a4% polymeric solution having a solvent system consisting ofacetone:water in the proportion of 89:11, weight to weight, directlyonto lamina h₁. Lamina h₂ had a thickness of 3 mils and a kπ₂ of 0.26cm³ ·mil/cm² · hr. Next, a third lamina h₃ was laminated to the freesurface of lamina h₂ to form laminated wall h_(T). Lamina h₃ consistedof 90 minutes hydrolyzed semipermeable polyvinyl acetate and it wasformed from a 4% polymeric solution in ethanol:water in the ratio of 90volumes of ethanol to 10 volumes of water. Lamina h₃ had a measuredthickness of 1 mil and a measured kπ₃ of 0.3 cm³ ·mil/cm² ·hr. Thelaminated wall h_(T) had a thickness of 4.5 mils, a kπ_(T) of 0.186 cm³·mil/cm² ·hr, and an area of 2.27 cm². A passageway through h_(T) had adiameter of 7 mils and the system had a rate of release of 30 mg per hr,with a variation of ±7% over a prolonged period of time.

EXAMPLE 6

The procedure of Example 5 is repeated but sodium chloride is replacedby nicotinamide, mannitol hexanitrate, isocarboxyazid, triamcinolone,tranylcyclopromine, meprobamate, nalamide, salicylamide, aspirin,theophylline, or theophylline monoethanolamine.

EXAMPLE 7

The physical and chemical integrity and the inertness of a laminatedwall to drug was demonstrated as follows: first, a 10% polymericsolution of polyvinyl alcohol, 98% hydrolyzed grade, in a mixture ofethanol:water in the proportion of 20 parts of ethanol to 80 parts ofwater, by weight, was prepared by stirring the polymer and solvent in ahigh shear blender at 95° C for 15 minutes. Then, a lamina of thepolymeric solution was cast with a Gardner knife onto a borosilicatesubstrate and dried at 40° C for 55 hours at atmospheric pressure.Finally, the lamina was crystallized in an oven at 170° C for 10minutes. The lamina identified as h₁ had a thickness of 1.8 mils.

Next, a 10% lamina forming solution consisting of polymeric celluloseacetate having an acetyl content of 32% dissolved in dioxane wasprepared by blending the polymer and the solvent in a high shear blenderfor 1 hr at 22.2° C and at atmospheric pressure. Then, a lamina h₂ ofthis lamina forming solution was cast with a Gardner knife directly ontothe total, exposed surface of lamina h₁. Lamina h₂ had a thickness of3.8 mils. Laminae h₁ and h₂ were dried in an oven for a week at 50° C toform a laminated wall that had a thickness h_(T) of 5.6 mils.

Then, the laminated wall was placed in an osmosis cell and its watertransmission value kπ_(T) was measured using the drug sodiumacetazolamide as an osmotic attractant. The laminated surface formed ofcrystallized semipermeable polyvinyl alcohol was placed in directcontact with the drug and the laminated surface of polymeric celluloseacetate was placed in contact with the environment consisting of water.The water transmission value for the laminated wall was measured for 6hrs. and found to be 0.16 cm³ ·mil/cm² ·hr. Then, a lamina h₁,consisting of crystallized polyvinyl alcohol as prepared above, wasplaced in the osmosis cell with one surface facing the drug and theother surface facing water, and its transmission value kπ₁ measured for8 hours. The transmission value found was 0.14 cm³ ·mil/cm² ·hr. Themeasurements were made at periodic intervals and the results obtainedwere recorded in FIG. 7. In the figure, lamina h₁ is 1 and the laminatedwall h₂, is 2. The results demonstrate the laminated wall maintains itsphysical and chemical integrity in the environment of use and towardsthe drug sodium acetazolamide. The results also show that lamina h₁ isnonerodible and inert to both the drug and the environment.

EXAMPLE 8

An osmotic therapeutic system for the controlled and continuous releaseof chlorpheniramine maleate is manufactured as follows: first, a 3%lamina forming solution of polymeric cellulose acetate having an acetylcontent of 38.3% in acetone and a multiplicity of drug cores consistingof 300 mgs of sodium chloride and 1,000 micrograms of chlorpheniraminemaleate are placed in a Wurster air suspension lamination machine andthe cores air tumbled until a uniform lamina h₁ is appliedto the drugcore. The lamina has a thickness of 0.5 mil and a kπ₁ of 0.054 cm³·mil/cm² ·hr. Next, a second lamina, h₂, forming solution consisting ofpolymeric cellulose acetate having an acetyl content of 32% inacetone:water solvent consisting of 89:11, weight to weight, is added tothe Wurster machine and lamina h₁ uniformly laminated with lamina h₂ toform the inert, laminated wall h_(t). Lamina h₂ is 3 mils thick and hada kπ₂ of 0.26 cm³ ·mils/cm² ·hr. The laminated wall has a thickness of3.5 mils and a kπ_(T) of 0.168 cm³ ·mils/cm² ·hr. Finally, an aperaturehaving a diameter of 7.5 mils is mechanically drilled through laminatedwall h_(T) to yield the osmotic therapeutic system. The laminated wallmaintains its physical and chemical integrity in the presence of drugand in the environment of use. The system has a controlled andcontinuous rate of release of about 100 micrograms per hourchloropheniramine maleate over a prolonged period of 10 hours.

EXAMPLE 9

The procedure of Example 8 is repeated with the lamination procedures aspreviously described, but the drug formulation of the example isreplaced with a member selected from the group consisting of calciumgluconate, calcium lactate, potassium sulfate, potassium fluoride,sodium fluoride, ferrous lactate, ferrous gluconate, ferrous sulfate,ferrous fumurate and sodium lactate which drug is released in aneffective amount at a controlled and continuous rate over a prolongedperiod of time.

The novel osmotic system of this invention use means for the obtainmentof precise release rate in the environment of use while simultaneouslymaintaining the integrity and character of the system. While there hasbeen described and pointed out features of the invention as applied topresently preferred embodiments, those skilled in the art willappreciate that various modifications, changes, additions and omissionsin the systems illustrated and described can be made without departingfrom the spirit of the invention.

We claim:
 1. An oral osmotic system sized and adapted for the controlledadministration of drug to an animal, said system comprising:a. a shapedlaminated wall comprising (1) a lamina formed of a material thatmaintains its physical and chemical integrity in the presence of fluid,drug and during the dispensing of drug, and is permeable to the passageof fluid and impermeable to the passage of drug, said lamina formed of amaterial having the general formula: ##STR4## wherein R₅ is a memberselected from the group consisting of hydroxyl, alkoxy, alkylcarbonate,alkylcarbamate, alkylsulfonate, alkylsulfamate and acyloxy, and whereinn is a positive number greater than 5 and at least one R is acyloxy,said lamina laminated to (2) a lamina formed of a different materialthat maintains its physical and chemical integrity in the presence offluid, drug and during the dispensing of drug, and is permeable to thepassage of fluid and impermeable to the passage of drug, said laminaformed of the different material selected from the general formula:##STR5## wherein R₅ is a member selected from the group consisting ofhydroxyl, alkoxy, alkylcarbonate, alkylcarbamate, alkylsulfonate,alkylsulfamate, and acyloxy, and wherein n is a positive number greaterthan 5 and at least one R is acyloxy; the wall surrounding and forming,b. a compartment containing a member selected from the group consistingof locally and systemically acting drugs; c. a passageway in the wallcommunicating with the compartment and the exterior of the system foradministering drug from the system; and, d. wherein in operation whenthe system is in the animal fluid therefrom is imbibed through thelaminated wall into the compartment in a tendency towards osmoticequilibrium at a rate determined by the permeability of the laminatedwall and the osmotic pressure gradient across the laminated wall therebycontinuously dissolving drug that is administered according to thefollowing equation:

    h.sub.T /kπ.sub.T = h.sub.1 /kπ.sub.1 + h.sub.2 /kπ.sub.2

wherein h_(T) is the thickness of the laminated wall, h₁ is thethickness of lamina (1,) h₂ is the thickness of lamina 2, kπ_(T) is theosmotic pressure of drug in the compartment times the permeability ofthe laminated wall to fluid, kπ₁ is the osmotic pressure of drug in thecompartment times the permeability of lamina (1) to fluid and kπ₂ is theosmotic pressure of drug in the compartment times the permeability oflamina (2) to fluid, through the passageway at a controlled andcontinuous rate over a prolonged period of time.
 2. The osmotic systemfor the controlled administration of drug according to claim 1, whereinthe acyloxy in lamina (1) is a member selected from the group consistingof alkanoxyloxy, alkenyloxy and aroyloxy and the degree of substitutionon each anhydroglucose unit is greater than from 0 up to
 3. 3. Theosmotic system for the controlled administration of drug according toclaim 1, wherein the acyloxy in lamina (2) is a member selected from thegroup consisting of formyloxy, acetyloxy, propionyloxy, valeryloxy,heptanoyloxy, octanoyloxy, underanoyloxy, lauroyloxy, palmitoyloxy,steroyloxy, oleoyloxy, acryloxyloxy, methacryloyloxy, crotomyloxy,butenoyloxy, benzoyloxy, phenylacetyloxy, cinnamoyloxy, naphthoyloxy,ethoxybenzyloxy, and furoyloxy.
 4. The osmotic system for the controlledadministration of drug according to claim 1, wherein the materialforming lamina (1) is a member selected from the group consisting ofcellulose acetate acetoacetate dimethoxyethylcellulose acetate,cellulose acetate benzoate, cellulose acetate dimethylsulfamate,ethylcellulose dimethylsulfamate, cellulose acetate methylcarbonate,cellulose acetate ethylcarbonate, cellulose acetate methylcarbamate andcellulose acetate ethylcarbamate.
 5. The osmotic system for thecontrolled administration of drug according to claim 1, wherein thematerial forming lamina (2) is a member selected from the groupconsisting of ethylmethylcellulose, hydroxyethylcellulose,hydroxypropylcellulose, hydroxyethyl methylcellulose, hydroxypropylmethylcellulose, ethylhydroxy ethylcellulose, and hexylpropyl cellulose.6. The osmotic system for the controlled administration of drugaccording to claim 1, wherein the drug is present in the compartmentmixed with an osmagent, and lamina (1) is formed of cellulose acetatehaving an acetyl content of 35 to 44.8%, and lamina (2) is formed ofcellulose acetate having an acetyl content of 21 to 35%.
 7. The osmoticsystem for the controlled administration of drug to an animal accordingto claim 1, wherein lamina (2) is formed of a member selected from thegroup consisting of cellulose triacetate, cellulose trivalerate,cellulose trilaurate, cellulose tripalmitate cellulose trisuccinate,cellulose triheptylate, cellulose tricaprylate, cellulose trioctanoateand cellulose tripropionate.
 8. The osmotic system for the controlledadministration of drug to an animal according to claim 1, wherein lamina(1) is formed of a member selected from the group consisting ofcellulose disuccinate, cellulose dipalmitate, cellulose dioctanoate,cellulose dicaprylate and cellulose dipentanoate.
 9. The osmotic systemfor the controlled administration of drug according to claim 1, whereinlamina (1) and lamina (2) exhibit a decreased permeability to thepassage of fluid as the size is increased of the substituting groupforming said laminae.
 10. The osmotic system for the controlledadministration of drug according to claim 1, wherein the compartmentcontains 0.05 ng to 5 grams of a drug that can be orally administered toproduce a beneficial result.
 11. The osmotic system for the controlledadministration of drug according to claim 1, wherein lamina (1) islaminated to lamina (2) by successive air suspension lamination using anorganic solvent selected from the group consisting of an alcohol,ketone, ester, ether, aliphatic hydrocarbon, halogenated hydrocarbon,cycloaliphatic aromatic, a heterocyclic, and solvent mixtures thereof.